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Molecular biologyBackground and aim: Folate metabolic pathway plays a significant role in leukemogenesis because of its
necessity for nucleotide synthesis and DNA methylation. Folate deficiency causes DNA damage. Thus
polymorphisms of folate-related genes may affect the susceptibility to childhood Acute Lymphoblastic
Leukemia (ALL).MTHFR (Methylenetetrahydrofolate Reductase), DHFR (Dihydrofolate reductase), CBS
(Cystathionine b-synthase) and TYMS (Thymidylate Synthase) have an important role in folate pathway
because their activated variants modulate synthesis of DNA and levels of folate. In this study, we aimed
to investigate whether polymorphisms in genes related to folate metabolic pathway influence the risk to
childhood ALL.
Subject and methods: The patient groups who were diagnosed with childhood ALL at Losante Pediatric
Hematology-Oncology Hospital and healthy control groups were included in the study. MTHFR 677 C-
T, MTHFR 1298 A-C, CBS 844ins68, DHFR 19-bp and TYMS 1494del6 polymorphisms were screened.
Genotyping of these polymorphisms was performed by Restriction Fragment Length Polymorphism
(RFLP) analysis and Real Time Polymerase chain Reaction (Real Time-PCR).
Results: In total, we have screened 5 polymorphisms in the studied genes. The results were compared
between childhood ALL patients and healthy groups. Genotype frequencies of MTHFR 677 C-T, MTHFR
1298 A-C, CBS 844ins68 and DHFR 19-bp del were similar for childhood ALL patients and healthy groups.
However, statistical results showed that TYMS 1494del6 may be associated with ALL pathogenesis
(p < 0.001).
Conclusion: We showed that TYMS polymorphism (rs2853542) may be associated with ALL pathogenesis.
In addition, our results demonstrated that MTHFR, DHFR and CBS do not affect development of leukemia.
Our study displays also importance as it is the first screening results to identify association with the stud-
ied polymorphisms in Turkish patients with childhood ALL and determination of the frequency in Turkish
population.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Folate is a water-soluble B vitamin included in one-carbon
metabolism that plays an essential role in synthesis, repair and
methylation of DNA. Several genes encoding metabolizing
enzymes are involved in the folate metabolic pathway. Polymor-
phisms in these genes alter the folate status or cause alterationin folate distribution. Deficiency of folate leads to DNA strand
breaks, chromosomal damage, reduced DNA repair, and aberrant
DNA methylation, thus affecting the susceptibility of ALL in chil-
dren. In the literature, some of polymorphisms in folate-related
genes have been described [1–4].
MTHFR is located on chromosome 1p36, consisted of 11 exons.
It is a key enzyme in folate pathway that catalyzes the reduction
of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate.
5-methyltetrahydrofolate acts as a carbon donor for DNA methyla-
tion [5,6].
The gene coding the DHFR cytosolic enzyme is located at the
long arm of chromosome 5 at position 11.2. DHFR is an enzyme
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NADPH as a cofactor. Tetrahydrofolate is required for de novo syn-
thesis of varieties of crucial metabolites involved in amino acids,
lipids, pyrimidines, and purines [7,8].
TYMS gene is located on chromosome 18q11.32, consisted of 7
exons. The gene which encodes TYMS enzyme converts deok-
sitimidin monofosfat (dTMP) to deoksiuridin monofosfat (dUMP).
This reaction is performed in the biosynthesis of pyrimidine
required for DNA replication and repair. 50 end of TYMS doesn’t
contain CAAT and TATA boxes [9,10].
The gene coding the CBS enzyme is located on chromosome
21q22.3, consisted of 23 exons. CBS enzyme is a member of the
pyridoxal 50 phosphate (PLP) family. CBS catalyzes the formation
of cystathionine from serine and homocysteine. CBS uses the PLP
as a cofactor [11,12].
MTHFR, DHFR, TYMS and CBS genes were chosen for screening
in this study because of their critical function in folate pathway.
Polymorphism in these genes can effect their activity in folate
pathway and susceptibility to development of leukemia. Therefore
our aim was to determine genotype distribution and allele fre-
quencies of common polymorphisms in these genes in the Turkish
childhood acute leukemia patients and their association with ALL.2. Subjects and methods
2.1. Subjects
The study population consisted of two main groups; the first
group was composed of childhood acute lymphoid leukemia
patients. The second group which is a control group was composed
of healthy individuals. Study population consisted of 180 patients
aged between 1 and 15 years who were admitted to Losante Pedi-
atric Hematology and Children’s Hospital with the diagnosis of
childhood acute leukemia.
Healthy groups were selected among healthy unrelated subjects
from Turkey (n: 296). An informed written consent was obtained
from all the patients’ parents. The study is carried out in accor-
dance with the code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.2.2. DNA isolation and Genotyping
Blood samples were collected with EDTA (Ethylenediaminete-
traacetic acid)-containing tubes and DNA was extracted from
peripheral blood and bone marrow leukocytes with MagNA Pure
automatic DNA isolation instrument (Roche Diagnostics, Manheim,
Germany).
Genotyping of MTHFR C677T (rs1801133) and A1298C
(rs1801131) polymorphisms analysis were performed by real-
time PCR (RT-PCR). Genotyping of polymorphisms were screened
with real time PCR using fluorescence melting curve detection
analysis by means of the Light Cycler 480 II System (Roche Diag-
nostics, Manheim, Germany).
Primers and probes used in MTHFR polymorphisms were as fol-
lows: MTHFR C677T; forward primer: 50-TGG CAG GTT ACC CCA
AAG G-30;reverse primer: 50-TGA TGC CCA TGT CGG TGC-30; anchor
hybridization probe: 50-LC–640-CGG GAG CCG ATT TCA TCA T-30-
PHO; Mutation probe: 50-TGA GGC TGA CCT GAA GCA CTT GAA
GGA GAA GGT GTC T-30-Flu) (TIB MOLBION, Berlin, Germany).
MTHFR A1298C; forward primer:50- CTT TGG GGA GCT GAA GGA
CTA CTA C -30;reverse primer: 50- CAC TTT GTG ACC ATT CCG
GTT TG -30; anchor hybridization probe: 50-LC–640- CTC CTC CCC
CCA CAT CTT CAG CAG -30-PHO; Mutation probe: 50- CTT CAA
AGA CAC TTT CTT CAC TGG TC -30-Flu.) (TIB MOLBION, Berlin,
Germany).Determination of 19-bp deletion polymorphism (rs1222809) of
DHFR and 68-bp insertion polymorphism of CBS were performed
using the conventional polymerase chain reaction. Then PCR prod-
ucts were analyzed by 3% agarose gel electrophoresis and stained
with ethidium bromide. The deletion/insertion was determined
based on the length of PCR products. Primers used in for DHFR
and CBS polymorphisms are as follows: DHFR 19-bp deletion; for-
ward primer-1: 50-CCA CCG TCG GGG TAC CTG GG-30; forward
primer-2: 50-ACG GTC GGG GTG GCC GAC TC-30; reverse primer:
50-AAA AGG GGA ATC CAG TCG G-30.
CBS 844ins68; forward primer-1: 50-CTG AAC ATT TAG GTC ATT
ACC-30; forward primer-2: 50-ACG GTC GGG GTG GCC GAC TC-30;
reverse primer: 50-TTT CAC ACG TTT TCC CTG C -30.
To determine the 1494del6 TYMS (rs2853542) polymorphism,
conventional PCR and RFLP methods were used. PCR products were
digested with the FastDigest HaeIII (Fermentas, Lithuania) restric-
tion enzyme. Primer used for the detection of TYMS 1494del6 were
as follows; forward primer-1: 50-CCA ATC TGA GGG AGC TGA GT-
30; reverse primer: 50-CAG ATA AGT GGC AGT ACA GA-30.2.3. Statistical analysis
The chi-square test was used to compare categorical variables. P
value of <0.05 was considered statistically significant. Allelic fre-
quencies were calculated by gene-counting method. Genotype dis-
tribution was analyzed for Hardy-Weinberg expectations by using
X2 and Fisher’s exact tests.3. Results
Genotype distributions and frequencies of gene polymorphisms
of MTHFR, DHFR, TYMS and CBS in Turkish children with acute leu-
kemia were given in Table 1.
The prevalence of MTHFR polymorphisms were determined for
180 childhood ALL patients and 296 healthy individuals. No signif-
icant difference for MTHFR 677 C-T genotypes frequency between
childhood leukemia patients and healthy group was found [(OR:
1.0 (0.6–1.5), CI%95; p = 0.8)].Similarly no difference was observed
in the distribution of MTHFR 1298 A-C genotypes frequency
between childhood ALL patients and healthy group [(OR: 1.48
(0.7–2.8), CI%95; p = 0.2)].
The prevalence of DHFR 19 bp deletion polymorphism was
determined for 63 childhood ALL patients and 296 healthy con-
trols. The prevalence of DHFR 19-bp deletion polymorphism was
similar in the study groups [(OR: 0.8 (0.4–1.6), CI%95; p = 0.5)].
For the 1494del6 TYMS polymorphism, we found that 124 (%
91.17) of the 136 patients were heterozygous. Heterozygosities
of 1494del6 TYMS polymorphisms demonstrated a significant dif-
ference between childhood ALL patients and healthy group [(OR:
0.09 (0.04–0.2) CI%95; p < 0.001).
When the CBS 844ins68 polymorphisms were examined, we
observed that there was no significant difference in the frequency
of heterozygosity genotype of CBS 844ins68 polymorphism
between childhood ALL patients and healthy group [(OR: 0,9
(0.5–1,8) CI%95; p: 0.9) .4. Discussion
ALL is the most common type of childhood malignancy. Genetic
and epigenetic alterations play a major role in ALL pathogenesis
such as gene mutations, deletions, translocations, and DNA methy-
lation [1,13,14]. Folates are required for many cellular processes
including methylation and synthesis of DNA. Deficiency of folate
causes imbalance in DNA precursors, misincorporation of uracil
Table 1
The genotype distribution of polymorphisms in childhood ALL and healthy groups.
MTHFR 677 C-T Childhood ALL n: 180 (%) Controls n:296 (%) OR/CI (%95) p
Genotype
CC 86 (47%) 141 (47.6%) 1
CT 78 (45.2%) 131 (44.2%) 1.0 (0.6–1.5) 0.8
TT 16 (7.5%) 24 (8%) 0.9 (0.4–1.8) 0.7
Allele (%)
C 0.69 0.69 1
T 0.31 0.31 1.7 (1.30–2.23) 0.0001
MTHFR 1298 A-C Childhood ALL n: 152 (%) Controls n:55 (%) OR/CI (%95) p
Genotype
A/A 64 (42.1%) 19 (35%) 1
A/C 75 (49.3%) 33 (60%) 1.48 (0.7–2.8) 0.2
C/C 13 (8.5%) 3 (5%) 0.7 (0.2–3.0) 0.9
Allele (%)
A 0.66 0.64 1
C 0.34 0.36 1.10 (0.70–1.75) 0.68
CBS 844ins68 Childhood ALL n:133 (%) *Controls n: 296 (%) OR/CI (%95) p
Genotype
wild/wild 117 (90%) 261 (88%) 1
wild/ins 16 (9.7%) 35 (11.8%) 0.9 (0.5–1.8) 0.95
ins/ins – – 0.4 (0.008–22.7) 0.5
Allele (%)
wild 0.93 0.94 1
ins 0.07 0.06 1.52 (0.982.39) 0.06
TYMS 1494del6 Childhood ALL n:136(%) Controls n:296 (%) OR/CI (%95) p
Genotype
6 bp/6 bp 8 (5.8%) 93 (31.4%) 1
+6bp/6 bp 124(92%) 147 (58.7%) 0.09 (0.04–0.2) 0.000001
+6bp/+6 bp 4(1.9%) 56 (18.9%) 1.2 (0.3–4.1) 0.9
Allele (%)
6 bp 0.51 0.56 1
+6 bp 0.49 0.44 0.82 (0.62–1.10) 0.18
DHFR 19-bp del Childhood ALLn:63(%) Controls n:296 (%) OR/CI (%95) p
Genotype
wild/ wild 30 (47%) 162 (54.7%) 1
wild/del 26 (41.2%) 117 (39.5%) 0.8 (0.4–1.6) 0.5
del/del 7 (11.1%) 17 (5.7%) 0.4 (0.1–1.1) 0.1
Allele (%)
wild 0.68 0.74 1
del 0.32 0.26 0.74 (0.48–1.11) 0.15
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need high amount of folate [15].
In the literature, numereos studies researched in Turkish popu-
lation, showed correlation between genetic polymorphisms of
folate metabolism pathway in different diseases [16–20]. However,
there is inadequate studies in development of childhood ALL [2,5,
8–11,13,21–25,28,31].
Therefore in this study we screened 5 polymorphisms in
MTHFR, TYMS, DHFR and CBS genes which are critical enzymes
involved in folate metabolic pathway and influence the risk of sev-
eral diseases associated with folate deficiency. We also investi-
gated the association of these polymorphisms with the
development of childhood ALL.
MTHFR is an enzyme associated with folate metabolism along
with DNA methylation and synthesis. MTHFR gene polymorphisms
are 677 C > T and 1298 A > C on the catalytic domain that are
responsible for a decrease in enzyme activity in variant allele car-
riers. Studies involved in this polymorphisms were shown that
folate deficiency is associated with leukemogenesis. There are
some of studies which demonstrated that there are significant cor-
relation between MTHFR polymorphisms and childhood ALL
patients [1,13,14,27–30,32,33]. Kuzelicki et al. reported that
decreased enzyme activity of MTHFR 677 TT genotype was associ-ated with Slovenian childhood ALL [32]. Another study preformed
by Damnjanovic et al. revealed that there was an important associ-
ation between CT + TT haplotype and reduced risk of Serbian child-
hood ALL. In addition, MTHFR 1298 polymorphism did not
demonstrate significant statistical difference in their study groups
[33].However, in our study, comparison of healthy group and
childhood ALL patients revealed no statistically significant differ-
ence in the 677 C-T and 1298 A-C genotype distribution. Our find-
ings have been supported by other studies which found no
significant difference in MTHFR 677 C-T and 1298 A-C frequencies
between childhood ALL patients and healthy group [21–24]. A
meta-analysis study was presented by Wang et al. did not find evi-
dence for a main role of MTHFR C677T in the leukemogenesis of
childhood ALL [25].
DHFR is one of the key folate-metabolizing enzymes that is nec-
essary for DNA synthesis and homocysteine remethylation. The
19 bp deletion polymorphism in intron 1 was associated with a
lower plasma level of homocysteine. The 19-bp wild type genotype
includes a binding site of Sp1 transcriptional factor at the intron 1
[8]. This polymorphism plays a role in the transcription of DHFR
and affects the amount of produced protein [26,34]. In our study,
screening of DHFR 19-bp del showed no statistically significant dif-
ference in childhood ALL patients compared to the healthy groups
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DHFR 19-bp deletion was brought 2.42 fold increased risk in adult
ALL [35]. But, to the best of our knowledge, there is no study that
investigates the association between childhood ALL and DHFR
19-bp deletion.
TYMS enzyme converts dUMP to dTMP required for DNA-
synthesis [28]. The TYMS polymorphism, a 6-bp insertion/deletion
(ins/del) is located at bp 1494 nucleotid in the region specifying
the mRNA 30UTR. This polymorphism has been proposed to affect
mRNA stability and translation [9,30]. It has been proposed that
the other polymorphism, tandem repeat 2R 3R, in 50 UTR of TYMS
have an association with development of leukemia [36]. In the pre-
sent study, we found that the leukemia risk was significantly high
in cases that carry heterozygote TYMS polymorphism (p = 0.001).
Milne et al. found that homozygosities of TYMS 6-bp ins/ins geno-
type brought a risk of leukemia between Australian childhood ALL
and healthy group (OR 1.8 (0.3–9.2) [30]. Therefore, our findings
supported their statistical results. However, Krajinovic et al.
screened TYMS polymorphisms in childhood ALL patients and
found no correlation with the development of leukemia. TYMS
3R/3R genotype had an effect on EFS (Event Free Survival) in Cana-
dian childhood ALL patients while 6 bp ins/del polymorphism did
not affect EFS [9].
The CBS enzyme is associated with trans-sulfuration pathway,
stimulating irreversible catalysis of homocysteine to cystathionine.
Previous studies reported that CBS 844ins68 polymorphism
affected activity of the enzyme and caused reduction in the levels
of homocysteine. In the present study, we found no significant dif-
ferences in the genotype frequency for 844ins68 polymorphism
between cases and healthy group (p = 0.5). A study performed by
Milne et al. have found that 55 (14%) of the 392 Australian child-
hood ALL patients carried heterozygous genotype (OR 0.79 0.53–
1.17) [30]. Franco et al. displayed same genotype frequency
between Brazilian childhood ALL patients and healthy group. OR
1(0.4–2.2) [31]. We suggested that the CBS 844ins68 polymor-
phism was not associated with childhood ALL patients.
In this study, we showed that polymorphisms of folate related
genes except TYMS do not affect development of leukemia because
the allele distributions are similar in childhood ALL patients and
healthy group. Polymorphisms of MTHFR, CBS and DHFR genotype
frequencies in study groups are similar. But importantly our results
showed that TYMS polymorphism may bring a risk for leukemia.
Doing further studies will be beneficial to verify these results with
a larger group of patients and in different populations.5. Conclusions
Our work carries scientific importance in three ways: First, the
screened polymorphisms in this article seem to be the first results
of studied genes in Turkish childhood ALL patients. Second, MTHFR
677 C-T, MTHFR 1298 A-C, CBS 844ins68 and DHFR 19-bp poly-
morphisms did not play an important role as genetic risk factors
for the development and progression of ALL. We found that TYMS
polymorphism (rs2853542) may be associated with development
of ALL as genetic risk factor. Three, the present study are helpful
to provide knowledge to other researchers about included gene
variations analyzed in folate metabolic pathway in childhood ALL
patients.Conflict of interest
The authors of this paper have no conflicts of interest, including
specific financial interests, relationships, and/or affiliations rele-
vant to the subject matter or materials included.References
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